CTSO - CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress | Benzinga
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present at the 1st Annual American Association of Physicians of Indian Origin (AAPI) World Health Congress, taking place on July 18-22, 2024 at the Mariott Marquis Hotel in New York, NY. This event will host over 3,000 physicians, healthcare professionals, and leaders from across the world for a dynamic exchange of ideas and a collaborative effort to shape the future of healthcare on a global scale. Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, will make a company presentation to the audience and was invited to separately participate in a panel discussion entitled "Convergence of Artificial Intelligence (AI) in Healthcare" on Saturday, July 20, 2024.
Dr. Chan commented, "I am pleased to have an opportunity to discuss, with my medical colleagues at AAPI, the important role that CytoSorb® and our other blood purification technologies are playing in the treatment of critically ill and cardiac surgery patients around the world. I am particularly excited to increase the awareness of CytoSorbents and our therapies amongst so many innovators in so many different fields of medicine."
Dr. Chan continued, "In addition, I look forward to sharing some thoughts during the panel discussion on how artificial intelligence can impact the field of critical care – one of the most challenging and costly areas of medicine today. For example, although AI is currently the prevailing buzz word, back in 2012 we were selected by the U.S. Defense Advanced Research Projects Agency (DARPA) as part of an academic and industry consortium to participate in its ambitious Dialysis-Like Therapeutics program to treat sepsis – the overwhelming immune response to an infection that is responsible for one in every five deaths worldwide each year. At that time, DARPA was already looking to develop a "smart" machine that could diagnose sepsis and its various causes, and selectively implement blood purification to remove the offending agents such as pathogens, cytokines, and bacterial toxins, to treat the disease. As part of the initial selection process, CytoSorbents and major industry collaborators in critical care that had access to an abundance of real-time patient data, worked together to propose a system that could not only diagnose and treat the disease, but could also correlate physiologic responses and clinical outcomes data, and through ...